Journal
OPEN LIFE SCIENCES
Volume 18, Issue 1, Pages -Publisher
DE GRUYTER POLAND SP Z O O
DOI: 10.1515/biol-2022-0533
Keywords
apatinib; NSCLC; zebrafish model; pemetrexed
Categories
Ask authors/readers for more resources
This study investigated the combined effect of apatinib and chemotherapeutic agents in treating non-small-cell lung cancer. The results suggest that the combination of apatinib and pemetrexed may be a promising alternative therapy for lung cancer patients.
Chemotherapy for advanced non-small-cell lung cancer (NSCLC) remains the first treatment choice. Angiogenesis inhibitors are effective for lung cancer treatment. This study explored whether chemotherapy combined with angiogenesis inhibitors could achieve better efficacy in NSCLC. The zebrafish A549 xenograft model was used to investigate the combined effect of apatinib and chemotherapeutic agents in NSCLC. Apatinib combined with pemetrexed demonstrated the highest antitumor effect compared with apatinib combined with gemcitabine or paclitaxel in vitro. In the zebrafish A549 xenograft model, apatinib and pemetrexed, alone or in combination, showed significant inhibition of tumor growth. Co-treatment with apatinib and pemetrexed demonstrated the best antitumor effects, suggesting that the combination of apatinib and pemetrexed might be a promising alternative therapy for patients with lung cancer. Apatinib combined with pemetrexed had enhanced antitumor effects compared with either one alone in the zebrafish model of NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available